bos-580
Recombinant proteinexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT04880031)
Timeline
Indications
Mechanism of action
- KlothoAGONIST
KL agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068114 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221188 | Phase 3 | Oct 31, 2025 | GlaxoSmithKline |
| NCT07221227 | Phase 3 | Oct 23, 2025 | GlaxoSmithKline |
| NCT06920043 | Phase 2 | Apr 9, 2025 | Boston Pharmaceuticals, GlaxoSmithKline |
| NCT04880031 | Phase 2 | Sep 30, 2021 | Boston Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 2 | 2 | 2025 |
| Boston Pharmaceuticals | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1